Price Chart

Executive Summary

Two shelf registration statements (File Nos. 333-286226 and 333-256611) for Forte Biosciences became effective on September 1, 2026. These shelves, originally filed in June 2026, each register up to $500M in securities, enabling the company to raise capital at any time. With a $1.6B market cap, the combined $1B shelf capacity represents ~63% of current market value, creating a persistent dilution overhang for a clinical-stage biopharma with no revenue and accelerating cash burn ($22.1M net loss in Q1 2026). The cross-filing actuarial verdict confirms this is an amplifier — the shelf effectiveness materially increases near-term equity issuance risk.

Key Facts

• Two shelf registration statements (333-286226 and 333-256611) became effective on September 1, 2026.
• Each shelf registers up to $500M in securities (common, preferred, debt, warrants, etc.), for a combined $1B capacity.
• Forte Biosciences is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026.
• The $1B shelf capacity represents ~63% of the current $1.6B market cap, signaling substantial potential dilution.
• The cross-filing actuarial verdict confirms this combo (IPO-context + shelf-context) is an amplifier, supporting an elevated impact score.

Financial Impact

Combined $1B shelf capacity vs $1.6B market cap (~63% potential dilution); company had $58.2M cash and $22.1M quarterly net loss as of Q1 2026

Risk Factors

• Imminent equity offering with significant dilution (~63% of market cap in shelf capacity)
• Accelerating cash burn ($22.1M quarterly loss) with limited cash runway ($58.2M)
• Clinical-stage biotech with no approved products or revenue

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status